These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 38814443

  • 1. Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes from men.
    Mäkinen S, Sree S, Ala-Nisula T, Kultalahti H, Koivunen P, Koistinen HA.
    Diabetologia; 2024 Sep; 67(9):1943-1954. PubMed ID: 38814443
    [Abstract] [Full Text] [Related]

  • 2. Activation of the hypoxia-inducible factor pathway protects against acute ischemic stroke by reprogramming central carbon metabolism.
    Madai S, Kilic P, Schmidt RM, Bas-Orth C, Korff T, Büttner M, Klinke G, Poschet G, Marti HH, Kunze R.
    Theranostics; 2024 Sep; 14(7):2856-2880. PubMed ID: 38773968
    [Abstract] [Full Text] [Related]

  • 3. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U, Signore PE, Walkinshaw G, Seeley TW, Brenner MC, Wang Q, Guo G, Arend MP, Flippin LA, Chow FA, Gervasi DC, Kjaergaard CH, Langsetmo I, Guenzler V, Liu DY, Klaus SJ, Lin A, Neff TB.
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [Abstract] [Full Text] [Related]

  • 4. Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
    Rahtu-Korpela L, Määttä J, Dimova EY, Hörkkö S, Gylling H, Walkinshaw G, Hakkola J, Kivirikko KI, Myllyharju J, Serpi R, Koivunen P.
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):608-17. PubMed ID: 26848160
    [Abstract] [Full Text] [Related]

  • 5. In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity.
    Eleftheriadis T, Pissas G, Mavropoulos A, Nikolaou E, Filippidis G, Liakopoulos V, Stefanidis I.
    Arch Immunol Ther Exp (Warsz); 2020 Oct 04; 68(6):31. PubMed ID: 33011826
    [Abstract] [Full Text] [Related]

  • 6. Contribution of HIF-P4H isoenzyme inhibition to metabolism indicates major beneficial effects being conveyed by HIF-P4H-2 antagonism.
    Tapio J, Halmetoja R, Dimova EY, Mäki JM, Laitala A, Walkinshaw G, Myllyharju J, Serpi R, Koivunen P.
    J Biol Chem; 2022 Aug 04; 298(8):102222. PubMed ID: 35787374
    [Abstract] [Full Text] [Related]

  • 7. Systemic inactivation of hypoxia-inducible factor prolyl 4-hydroxylase 2 in mice protects from alcohol-induced fatty liver disease.
    Laitakari A, Ollonen T, Kietzmann T, Walkinshaw G, Mennerich D, Izzi V, Haapasaari KM, Myllyharju J, Serpi R, Dimova EY, Koivunen P.
    Redox Biol; 2019 Apr 04; 22():101145. PubMed ID: 30802717
    [Abstract] [Full Text] [Related]

  • 8. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
    Yang Y, Yu X, Zhang Y, Ding G, Zhu C, Huang S, Jia Z, Zhang A.
    Clin Sci (Lond); 2018 Apr 16; 132(7):825-838. PubMed ID: 29581249
    [Abstract] [Full Text] [Related]

  • 9. Impaired glucose partitioning in primary myotubes from severely obese women with type 2 diabetes.
    Zou K, Turner K, Zheng D, Hinkley JM, Kugler BA, Hornby PJ, Lenhard J, Jones TE, Pories WJ, Dohm GL, Houmard JA.
    Am J Physiol Cell Physiol; 2020 Dec 01; 319(6):C1011-C1019. PubMed ID: 32966127
    [Abstract] [Full Text] [Related]

  • 10. Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.
    Huang H, Wang X, Zhang X, Wang H, Jiang W.
    Toxicol Lett; 2020 Oct 01; 331():112-121. PubMed ID: 32534005
    [Abstract] [Full Text] [Related]

  • 11. Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice.
    Deguchi H, Ikeda M, Ide T, Tadokoro T, Ikeda S, Okabe K, Ishikita A, Saku K, Matsushima S, Tsutsui H.
    Circ J; 2020 May 25; 84(6):1028-1033. PubMed ID: 32213720
    [Abstract] [Full Text] [Related]

  • 12. Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects. Comparison using human skeletal muscle cell cultures.
    Henry RR, Abrams L, Nikoulina S, Ciaraldi TP.
    Diabetes; 1995 Aug 25; 44(8):936-46. PubMed ID: 7622000
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
    Beck J, Henschel C, Chou J, Lin A, Del Balzo U.
    Int J Toxicol; 2017 Aug 25; 36(6):427-439. PubMed ID: 29153032
    [Abstract] [Full Text] [Related]

  • 14. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action.
    Chang WT, Lo YC, Gao ZH, Wu SN.
    Int J Mol Sci; 2019 Nov 29; 20(23):. PubMed ID: 31795416
    [Abstract] [Full Text] [Related]

  • 15. TNF-α-induced NF-κB activation stimulates skeletal muscle glycolytic metabolism through activation of HIF-1α.
    Remels AH, Gosker HR, Verhees KJ, Langen RC, Schols AM.
    Endocrinology; 2015 May 29; 156(5):1770-81. PubMed ID: 25710281
    [Abstract] [Full Text] [Related]

  • 16. Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury.
    Han F, Wu G, Han S, Li Z, Jia Y, Bai L, Li X, Wang K, Yang F, Zhang J, Wang X, Guan H, Linlin S, Han J, Hu D.
    Respir Physiol Neurobiol; 2020 Oct 29; 281():103506. PubMed ID: 32726645
    [Abstract] [Full Text] [Related]

  • 17. HIF-P4H-2 deficiency protects against skeletal muscle ischemia-reperfusion injury.
    Karsikas S, Myllymäki M, Heikkilä M, Sormunen R, Kivirikko KI, Myllyharju J, Serpi R, Koivunen P.
    J Mol Med (Berl); 2016 Mar 29; 94(3):301-10. PubMed ID: 26452676
    [Abstract] [Full Text] [Related]

  • 18. Regulation of skeletal muscle sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) by metabolic stress and diabetes.
    Rune A, Osler ME, Fritz T, Zierath JR.
    Diabetologia; 2009 Oct 29; 52(10):2182-9. PubMed ID: 19652946
    [Abstract] [Full Text] [Related]

  • 19. HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction.
    Rahtu-Korpela L, Karsikas S, Hörkkö S, Blanco Sequeiros R, Lammentausta E, Mäkelä KA, Herzig KH, Walkinshaw G, Kivirikko KI, Myllyharju J, Serpi R, Koivunen P.
    Diabetes; 2014 Oct 29; 63(10):3324-33. PubMed ID: 24789921
    [Abstract] [Full Text] [Related]

  • 20. Esterification promotes the intracellular accumulation of roxadustat, an activator of hypoxia-inducible factors, to extend its effective duration.
    Nakai T, Saigusa D, Iwamura Y, Matsumoto Y, Umeda K, Kato K, Yamaki H, Tomioka Y, Hirano I, Koshiba S, Yamamoto M, Suzuki N.
    Biochem Pharmacol; 2022 Mar 29; 197():114939. PubMed ID: 35114188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.